The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Early prediction of clinical response to first-line treatment with gefitinib using integrated FDG-PET for patients with advanced non-small cell lung cancer.
M. Kanadzu
No relevant relationships to disclose
K. Asami
No relevant relationships to disclose
S. Hamaguchi
No relevant relationships to disclose
Y. Kurahara
No relevant relationships to disclose
T. Tsuji
No relevant relationships to disclose
K. Nakao
No relevant relationships to disclose
K. Nishie
No relevant relationships to disclose
T. Goto
No relevant relationships to disclose
A. Hirooka
No relevant relationships to disclose
N. Takeuchi
No relevant relationships to disclose
T. Kagawa
No relevant relationships to disclose
A. Tamiya
No relevant relationships to disclose
Y. Matsuda
No relevant relationships to disclose
H. Yamanaka
No relevant relationships to disclose
K. Okishio
No relevant relationships to disclose
T. Kawaguchi
No relevant relationships to disclose
S. Atagi
No relevant relationships to disclose
K. Maruyama
No relevant relationships to disclose
M. Takada
No relevant relationships to disclose